David T. Wong

5.0k total citations · 3 hit papers
47 papers, 4.0k citations indexed

About

David T. Wong is a scholar working on Molecular Biology, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, David T. Wong has authored 47 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 18 papers in Pharmacology and 18 papers in Cellular and Molecular Neuroscience. Recurrent topics in David T. Wong's work include Neurotransmitter Receptor Influence on Behavior (16 papers), Treatment of Major Depression (12 papers) and Receptor Mechanisms and Signaling (8 papers). David T. Wong is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (16 papers), Treatment of Major Depression (12 papers) and Receptor Mechanisms and Signaling (8 papers). David T. Wong collaborates with scholars based in United States, United Kingdom and Canada. David T. Wong's co-authors include Frank P. Bymaster, Frank P. Bymaster, Eric A. Engleman, Kenneth W. Perry, Jong S. Horng, Nicholas Moore, Julie F. Falcone, Philip Seeman, N.C. Tye and David O. Calligaro and has published in prestigious journals such as Nature, Science and Nature Reviews Drug Discovery.

In The Last Decade

David T. Wong

46 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

1996 855 citations Frank P. Bymaster, David O. Calligaro et al. Neuropsychopharmacology profile →
Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication

1995 552 citations David T. Wong, Frank P. Bymaster et al. Life Sciences profile →
A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-Trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine

1974 374 citations David T. Wong, Jong S. Horng et al. Life Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David T. Wong United States	27	1.7k	1.5k	819	777	488	47	4.0k
Silvio Caccia Italy	44	2.4k 1.5×	1.5k 1.0×	964 1.2×	1.0k 1.3×	485 1.0×	194	5.8k
M. Da Prada Switzerland	42	2.3k 1.4×	2.2k 1.5×	568 0.7×	737 0.9×	334 0.7×	142	6.7k
J. David Leander United States	40	3.2k 1.9×	2.3k 1.5×	495 0.6×	610 0.8×	641 1.3×	167	5.1k
P. C. Waldmeier Switzerland	40	2.8k 1.6×	2.3k 1.6×	608 0.7×	562 0.7×	244 0.5×	155	5.2k
W Gommeren Belgium	30	2.3k 1.4×	1.9k 1.3×	1000 1.2×	425 0.5×	193 0.4×	55	4.2k
Hans Rommelspacher Germany	43	2.5k 1.5×	2.3k 1.6×	376 0.5×	744 1.0×	635 1.3×	178	5.4k
J.E. Leysen Belgium	38	3.6k 2.1×	2.8k 1.9×	1.3k 1.6×	635 0.8×	285 0.6×	97	6.1k
Theodore L. Sourkes Canada	40	2.0k 1.2×	1.6k 1.1×	583 0.7×	502 0.6×	249 0.5×	258	5.5k
Hans Rollema United States	35	2.6k 1.6×	3.0k 2.0×	735 0.9×	604 0.8×	358 0.7×	110	5.4k
Michael G. Palfreyman France	32	1.8k 1.1×	1.3k 0.9×	454 0.6×	362 0.5×	329 0.7×	99	3.3k

Countries citing papers authored by David T. Wong

Since Specialization

Citations

This map shows the geographic impact of David T. Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Wong more than expected).

Fields of papers citing papers by David T. Wong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Wong. The network helps show where David T. Wong may publish in the future.

Co-authorship network of co-authors of David T. Wong

This figure shows the co-authorship network connecting the top 25 collaborators of David T. Wong. A scholar is included among the top collaborators of David T. Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T. Wong. David T. Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

White, James D., et al.. (2009). Synthesis of 1,1-[1-Naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and Their Evaluation as Inhibitors of Serotonin, Norepinephrine, and Dopamine Transporters. Journal of Medicinal Chemistry. 52(19). 5872–5879. 9 indexed citations

Wong, David T., Kenneth W. Perry, & Frank P. Bymaster. (2005). The Discovery of Fluoxetine Hydrochloride (Prozac). Nature Reviews Drug Discovery. 4(9). 764–774. 311 indexed citations

Bymaster, Frank P., Jeremy Findlay, P. T. Gallagher, et al.. (2004). Duloxetine (Cymbalta), a Dual Inhibitor of Serotonin and Norepinephrine Reuptake.. ChemInform. 35(12). 5 indexed citations

Rocco, Vincent P., Todd J. Kohn, David L. Nelson, et al.. (2004). Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4. Bioorganic & Medicinal Chemistry Letters. 14(10). 2653–2656. 30 indexed citations

Takeuchi, Kumiko, Todd J. Kohn, Vincent P. Rocco, et al.. (2003). Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 3. Bioorganic & Medicinal Chemistry Letters. 13(22). 3939–3942. 18 indexed citations

Takeuchi, Kumiko, Todd J. Kohn, Vincent P. Rocco, et al.. (2003). Advances Toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 2. Bioorganic & Medicinal Chemistry Letters. 13(14). 2393–2397. 20 indexed citations

Takeuchi, Kumiko, Todd J. Kohn, Vincent P. Rocco, et al.. (2003). Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 1. Bioorganic & Medicinal Chemistry Letters. 13(11). 1903–1905. 45 indexed citations

Wong, David T. & Frank P. Bymaster. (2002). Dual serotonin and noradrenaline uptake inhibitor class of antidepressants — Potential for greater efficacy or just hype?. Birkhäuser Basel eBooks. 58. 169–222. 92 indexed citations

Bymaster, Frank P., et al.. (1997). Olanzapine increases extracellular dopamine release and blocks dopamine, serotonin and muscarinic receptors in vivo. Schizophrenia Research. 24(1-2). 74–74. 2 indexed citations

10.

Bymaster, Frank P., David O. Calligaro, Julie F. Falcone, et al.. (1996). Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine. Neuropsychopharmacology. 14(2). 87–96. 855 indexed citations breakdown →

11.

Wong, David T., Frank P. Bymaster, & Eric A. Engleman. (1995). Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sciences. 57(5). 411–441. 552 indexed citations breakdown →

12.

Mitch, Charles H., J. David Leander, Laurane G. Mendelsohn, et al.. (1993). 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity. Journal of Medicinal Chemistry. 36(20). 2842–2850. 50 indexed citations

13.

Wong, David T., et al.. (1993). LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake. Neuropsychopharmacology. 8(1). 23–33. 187 indexed citations

14.

Ornstein, Paul L., John M. Schaus, John Whiteclay Chambers, et al.. (1989). Synthesis and pharmacology of a series of 3- and 4-(phosphonoalkyl)pyridine- and -piperidine-2-carboxylic acids. Potent N-methyl-D-aspartate receptor antagonists. Journal of Medicinal Chemistry. 32(4). 827–833. 49 indexed citations

15.

McQuaid, Loretta A., et al.. (1989). Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity. Journal of Medicinal Chemistry. 32(10). 2388–2396. 14 indexed citations

16.

Robertson, David W., et al.. (1988). Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor. Journal of Medicinal Chemistry. 31(1). 185–189. 70 indexed citations

17.

Lemberger, Louis, et al.. (1978). Pharmacologic Effects in Man of a Specific Serotonin-Reuptake Inhibitor. Science. 199(4327). 436–437. 36 indexed citations

18.

Lemberger, Louis, Howard Rowe, Ross E. Crabtree, et al.. (1978). Fluoxetine, a selective serotonin uptake inhibitor. Clinical Pharmacology & Therapeutics. 23(4). 421–429. 88 indexed citations

19.

Wong, David T., et al.. (1972). Robenzidene, an inhibitor of oxidative phosphorylation. Biochemical and Biophysical Research Communications. 46(2). 621–627. 10 indexed citations

20.

Wong, David T., et al.. (1971). Respiratory Chain of a Pathogenic Fungus, Microsporum gypseum : Effect of the Antifungal Agent Pyrrolnitrin. Journal of Bacteriology. 106(1). 168–173. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact